Has John Kaczmar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $19,917 in general payments to John Kaczmar, MD across 45 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Kaczmar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Kaczmar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Kaczmar, MD

Medical Oncology · Charleston, SCNPI 1134448079

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,531 of the $19,917 with a category attached, or 73.0%. 11 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 42.2% of the total. Reporting peaked in 2019 at $8,489 and has fallen 55.4% since, to $3,782 in 2025.

$19,917in general payments, 2019–2025

Across 45 payments — averaging $442.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Regeneron Healthcare Solutions, Inc.$8K
Regeneron$6K
EMD Serono, Inc.$3K
Coherus Oncology, Inc.$2K
Stryker$253
Ipsen Biopharmaceuticals, Inc$241
plus $187 from 5 others

$7,738,232in research payments, 2019–2025

Across 284 payments — averaging $27,247 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$6.8M
Regeneron$337K
Ascendis Pharma Endocrinology Inc$145K
GSK$142K
AVEO Pharmaceuticals, Inc.$131K
Merck Healthcare Kgaa$76K
plus $77K from 5 others

What the payments were for

Consulting fees$14,53173%
Travel & lodging$1,6818%
Food & beverage$2,30612%
Education$1,3997%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Regeneron Healthcare Solutions, Inc.	14	$8,402
Regeneron	16	$5,917
EMD Serono, Inc.	3	$2,694
Coherus Oncology, Inc.	3	$2,223
Stryker	2	$253
Ipsen Biopharmaceuticals, Inc	2	$241
Axogen	1	$71
Tactile Systems Technology Inc	1	$49
Caris MPI, Inc.	1	$34
Merck	1	$18
E.r. Squibb & Sons, L.L.C.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,917 in reported general payments places this provider in the 85th percentile of 29 medical oncology providers in South Carolina.

See all medical oncology providers in South Carolina →

Medicare billing

Part B allowed, 2024

$69,876

Medicare patients

238

Services billed

952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
LenvimaLenvatinib Mesylate	23	$567,491
ErivedgeVismodegib	11	$114,446
EliquisApixaban	14	$9,189
Oxycodone Hcl	42	$1,253
Prochlorperazine Maleate	89	$1,092
Ondansetron Hcl	81	$1,040
Levothyroxine Sodium	50	$444
Gabapentin	23	$349
Triamcinolone Acetonide	12	$248
Lidocaine Hcl ViscousLidocaine Hcl	12	$196
Prednisone	40	$194
Dexamethasone	13	$165
Duloxetine Hcl	13	$118
Escitalopram Oxalate	11	$68
Hydrochlorothiazide	17	$7

Paid to pharmacies, not to this prescriber.

Other medical oncology in Charleston

Albert LockhartCharleston$54K
Gene SaylorsCharleston$26K
Mariam AlexanderCharleston$23K
Theodore GourdinCharleston$21K
Kevin BeckerCharleston$9K
Scott LindhorstCharleston$7K
Carolyn BrittenCharleston$2K
Rodney WilliamsCharleston$1K
Oleksandra LupakCharleston$313
Michael LillyCharleston$249

See the full list for South Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →